17 December 2021 - The approval follows a successful period of monitoring and patient access through the Cancer Drugs Fund.

NICE has issued guidance recommending Merck/MSD’s Keytruda (pembrolizumab) for routine commissioning, for use as a monotherapy for the adjuvant treatment of adults with stage 3 melanoma with lymph node involvement who have undergone complete resection.

Read Pharma Times article